Ambryon Biosciences

Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting

Sun et al. (2019). Acta Pharm. Sin. B·Citations: 18Research

The first human anti-IL-17A antibody 7H9 had modest potency and poor thermostability. Affinity maturation gave 8D3, with CDRs grafted onto 4D5 as 9NT/S. 8D3 neutralized IL-17A 15-fold better than 7H9, and grafting raised Fab melting temperature to 77C from 59.4C.

Key finding

  • Yeast-display random mutagenesis of anti-IL-17A mAb 7H9, isolated from a naïve phage-displayed scFv library, gave clone 8D3, whose four key amino acid substitutions produced an approximately 15-fold gain in cell-based neutralization potency over 7H9.

Author abstract

Monoclonal antibodies (mAbs) are widely used in many fields due to their high specificity and ability to recognize a broad range of antigens. IL-17A can induce a rapid inflammatory response both alone and synergistically with other proinflammatory cytokines. Accumulating evidence suggests that therapeutic intervention of IL-17A signaling offers an attractive treatment option for autoimmune diseases and cancer. Here, we present a combinatorial approach for optimizing the affinity and thermostability of a novel anti-hIL-17A antibody. From a large naïve phage-displayed library, we isolated the anti-IL-17A mAb 7H9 that can neutralize the effects of recombinant human IL-17A. However, the modest neutralization potency and poor thermostability limit its therapeutic applications. In vitro affinity optimization was then used to generate 8D3 by using yeast-displayed random mutagenesis libraries. This resulted in four key amino acid changes and provided an approximately 15-fold potency increase in a cell-based neutralization assay. Complementarity-determining regions (CDRs) of 8D3 were further grafted onto the stable framework of the huFv 4D5 to improve thermostability. The resulting hybrid antibody 9NT/S has superior stabilization and affinities beyond its original antibody. Human fibrosarcoma cell-based assays and in vivo analyses in mice indicated that the anti-IL-17A antibody 9NT/S efficiently inhibited the secretion of IL-17A-induced proinflammatory cytokines. Therefore, this lead anti-IL-17A mAb might be used as a potential best-in-class candidate for treating IL-17A related diseases.

Identifiers & revision